Zhang X, Li J, Fu M, Geng X, Hu J, Tang K
Respir Res. 2025; 26(1):29.
PMID: 39833797
PMC: 11749457.
DOI: 10.1186/s12931-025-03099-8.
Krause P, McGeorge G, McPeek J, Khalid S, Nelin L, Liu Y
Physiol Rep. 2024; 12(20):e70089.
PMID: 39435735
PMC: 11494452.
DOI: 10.14814/phy2.70089.
Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R
J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.
PMID: 39388691
PMC: 11502635.
DOI: 10.1089/jamp.2024.0016.
Ntiloudi D, Kasinos N, Kalesi A, Vagenakis G, Theodosis-Georgilas A, Rammos S
Diagnostics (Basel). 2024; 14(18).
PMID: 39335731
PMC: 11431164.
DOI: 10.3390/diagnostics14182052.
Zhu M, Dai J, Dai Z, Peng Y, Zhao Y
JCI Insight. 2024; 9(20).
PMID: 39316438
PMC: 11530134.
DOI: 10.1172/jci.insight.177926.
miR-30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil.
Liang X, Zhou J, Wang H, Zhang Z, Yin M, Zhu Y
Adv Sci (Weinh). 2024; 11(40):e2407712.
PMID: 39206778
PMC: 11516105.
DOI: 10.1002/advs.202407712.
Chemical Constituents with Anti-Proliferative Activity on Pulmonary Arterial Smooth Muscle Cells from the Roots of (L.) Hoffm.
Liu Y, Cao Y, Zheng Y, Niu Y, Chen L, Chen X
Molecules. 2024; 29(11).
PMID: 38893423
PMC: 11173479.
DOI: 10.3390/molecules29112547.
Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications.
Novara M, Di Martino E, Stephens B, Nayrouz M, Vitulo P, Carollo A
Drugs R D. 2024; 24(1):13-28.
PMID: 38514585
PMC: 11035521.
DOI: 10.1007/s40268-024-00453-x.
Case report: Extracorporeal life support as a successful bridge to recovery in an incident case of pulmonary arterial hypertension.
Pequignot B, Chaouat A, Chabot F, Levy B, Valentin S
Front Med (Lausanne). 2024; 11:1283065.
PMID: 38379558
PMC: 10876800.
DOI: 10.3389/fmed.2024.1283065.
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
Tornling G, Edenius C, Pauling J, Denton C, Olsson A, Kowalski J
Rheumatology (Oxford). 2024; 64(2):704-713.
PMID: 38291895
PMC: 11781579.
DOI: 10.1093/rheumatology/keae049.
The novel roles of YULINK in the migration, proliferation and glycolysis of pulmonary arterial smooth muscle cells: implications for pulmonary arterial hypertension.
Wu Y, Wang W, Yang M, Su Y, Yeh J, Hsu J
Biol Res. 2023; 56(1):66.
PMID: 38057829
PMC: 10702011.
DOI: 10.1186/s40659-023-00480-z.
The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension.
Ye L, Wang B, Xu H, Zhang X
Metabolites. 2023; 13(11).
PMID: 37999248
PMC: 10672796.
DOI: 10.3390/metabo13111152.
Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
Omura J, Makanji Y, Tanabe N, Yu D, Tan J, Lim S
Pulm Ther. 2023; 9(4):511-526.
PMID: 37991630
PMC: 10721767.
DOI: 10.1007/s41030-023-00244-w.
A Case of Giant Goiter Associated with Airway Stenosis Caused by Long-Term Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension.
Nishiura K, Nakazato K, Yokokawa T, Suzuki Y, Kurosawa Y, Wada K
J Clin Med. 2023; 12(19).
PMID: 37835003
PMC: 10573889.
DOI: 10.3390/jcm12196359.
In the Search for Biomarkers of Pulmonary Arterial Hypertension, Are Cytokines IL-2, IL-4, IL-6, IL-10, and IFN-Gamma the Right Indicators to Use?.
Tomaszewski M, Mertowska P, Janczewska M, Styczen A, Mertowski S, Jonas K
Int J Mol Sci. 2023; 24(18).
PMID: 37761997
PMC: 10530884.
DOI: 10.3390/ijms241813694.
Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study.
Naranjo M, Rosenzweig E, Hemnes A, Jacob M, Desai A, Hill N
Pulm Circ. 2023; 13(3):e12281.
PMID: 37614830
PMC: 10442608.
DOI: 10.1002/pul2.12281.
Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials.
Awad A, Reda Gad E, Abdelgalil M, Elsaeidy A, Ahmed O, Elbadawy M
BMC Pediatr. 2023; 23(1):372.
PMID: 37474896
PMC: 10360284.
DOI: 10.1186/s12887-023-04180-1.
Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns.
Yildirim S
Pulm Circ. 2023; 13(3):e12268.
PMID: 37469523
PMC: 10352650.
DOI: 10.1002/pul2.12268.
Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives.
Coons J, Empey P
Pharmgenomics Pers Med. 2023; 16:729-737.
PMID: 37457231
PMC: 10349598.
DOI: 10.2147/PGPM.S361222.
Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients' prognosis.
Huang J, An Q, Shi H, Li C, Zhang W, Wang L
Clin Rheumatol. 2023; 42(11):3131-3142.
PMID: 37382842
DOI: 10.1007/s10067-023-06667-9.
